A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
Description
Brief Summary
The primary objective of this study was to assess the long term safety of fostamatinib in
subjects with persistent/chronic ITP
Phase
Phase 3 - a treatment has shown activity against a particular disease, where it is either added to existing treatment or compared to the standard treatment.Inclusion and Exclusion Criteria
- Completed week 24 evaluation of Study C935788-047 or Study C935788-048 or discontinued early due to lack of response.
- Able and willing to give written informed consent
- Discontinued participation in Study C935788-047 or Study C935788-048 for any reason other than lack of response
- Poorly controlled hypertension during Study C935788-047 or Study C935788-048
- Significant infection, an acute infection such as influenza, or known inflammatory process
Sites
Please contact Poornima Murali to learn more about where you can participate in this trial. Please use the contact form on the right side.